Loading clinical trials...
Loading clinical trials...
A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors
Conditions
Interventions
BP31510 monotherapy
BP31510 in combination with chemotherapy
Locations
3
United States
Palo Alto Medical Foundation
Sunnyvale, California, United States
Weill Cornell Solid Tumor Oncology Practice
New York, New York, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
October 1, 2013
Primary Completion Date
February 1, 2017
Completion Date
February 1, 2017
Last Updated
February 19, 2025
NCT06132828
NCT04541381
NCT04570423
NCT06144671
NCT05468034
NCT03137095
Lead Sponsor
BPGbio
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions